Accelerate Stroke Therapeutic Development with the Rat tMCAO Model
The transient middle cerebral artery occlusion (tMCAO) model is considered the gold standard preclinical model for ischemic stroke research, providing a robust platform for evaluating neuroprotective and neurorestorative therapies.
This case study highlights the neuroprotective activity of Edaravone following focal cerebral ischemia and reperfusion, demonstrating measurable improvements across multiple efficacy endpoints.
Download this case study to see:
Download the case study to discover how our preclinical stroke models can support your therapeutic development programs.
A systematic introduction to Ace Therapeutics' preclinical stroke research capabilities and cutting-edge technology platforms.
Ace Therapeutics provides customized stroke models and technology platforms to support preclinical stroke research.
Our customized in vitro models of stroke and advanced cell-based assay platform accelerate the discovery of novel stroke therapies.
Photochemical thrombosis is a method for the induction of ischemic stroke in the cerebral cortex, which aids in stroke mechanism and therapy development.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.